Insmed Incorporated (NASDAQ:INSM) Given Consensus Recommendation of "Buy" by Analysts

Shares of Insmed Incorporated (NASDAQ:INSM - Get Free Report) have been given a consensus recommendation of "Buy" by the sixteen brokerages that are currently covering the firm, Marketbeat.com reports. Sixteen analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $83.67.

Several research firms have recently weighed in on INSM. Bank of America upped their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Truist Financial reiterated a "buy" rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Monday, September 9th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a research report on Friday, November 22nd.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Insmed

Several large investors have recently modified their holdings of INSM. V Square Quantitative Management LLC purchased a new stake in Insmed in the 3rd quarter worth approximately $30,000. GAMMA Investing LLC raised its holdings in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 224 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after acquiring an additional 627 shares during the period. Blue Trust Inc. boosted its holdings in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company's stock valued at $131,000 after acquiring an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. purchased a new position in Insmed during the 3rd quarter valued at $133,000.

Insmed Stock Performance

Shares of NASDAQ INSM traded down $0.51 during mid-day trading on Tuesday, hitting $66.11. The company had a trading volume of 2,144,350 shares, compared to its average volume of 1,602,412. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a 1 year low of $21.92 and a 1 year high of $80.53. The company has a market capitalization of $11.83 billion, a price-to-earnings ratio of -11.91 and a beta of 1.12. The stock's 50-day moving average price is $71.51 and its 200-day moving average price is $72.55.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period in the previous year, the firm earned ($1.10) earnings per share. The firm's quarterly revenue was up 18.1% on a year-over-year basis. On average, sell-side analysts forecast that Insmed will post -5.44 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.